Good luck to you and god bless you. Please let us know how it went for you and keep us posted thanks.
i did 24 weeks of BI201335..phase 2 trial..stage 4/early cirrhosis ......was undetected 2 weeks in and since...went for 6 month post tx blood today......fingers crossed good luck
Thanks for your feedback. I've done more research on the mk7009 and it appears promising, however, I know so little but learning daily. I amp type 1, with damage at Stage 3.
I was able to google your study drugs, I believe the NCT00793793 may belong to bi201335na . and Mk5172 is new while mk7009 now has the name vaniprevir. by Merck. A link is www.msd-bahamas.com/newsroom/2010_0414.html Im sorry I dont know if eighter one of these study drugs are good or not , but maybe other people on this forum. can help you. good luck
Yes, you absolutely need to research these. Frantically searching for any trial just to get in isn't a good idea. If I remember right, you're recently infected, and probably have no damage - if that's the case, there's really no rush.
Check the trials carefully. What were the phase 1 results like? What are the research papers saying about the drug? What were the side effects, and how did they compare to the placebo arm?
Trials can be a godsend, if they're entered into from a position of careful thought.
Good luck, be smart!
Thanks FIGuy & nygirl7; I'll look into these ...
You should really try to get the ClinicalTrials.gov Identifier numbers for these trials. I looked at a few (not sure which one is your potential) and looked a little "iffy". You need to know what you're getting yourself into. A clinical trial number will look something like : NCT00984620
I'm sorry I dont know but if you put HCV into google you can see a bunch of hcv trial drugs got told no go by the FDA. You have to be very very careful when deciding exactly which trial to go into.
I'm not saying it about these but I'd be very sure before I got into a trial EXACTLY where you stand.
Novartis and HGS Ditch HCV Drug as EMEA and FDA Express Risk-Benefit Concerns
Genetic Engineering News - Oct 5, 2010
Novartis and Human Genome Sciences (HGS) have canned further development of their registrational chronic hepatitis C (HCV) candidate Zalbin™/Joulferon® ...
HGS, Novartis Bail on Zalbin After Thumbs Down from FDA
BioWorld Online - Catherine Shaffer - 18 hours ago
Inc.'s HCV protease inhibitor boceprevir and Pharmasset Inc.'s nucleotide analogue polymerase inhibitor PSI-7977. The absence of Zalbin may give the ...